Biohaven’s BHV-7000 program must pause new enrollment after the FDA imposed a partial clinical hold tied to a metabolite, while more than 1,200 participants have been dosed. Dosing can continue for randomized patients, and the fully enrolled BHV7000-303 study remains on track for a topline readout in the second half of 2026.
Key Highlights
- BHV7000-303 is evaluating a 75 mg dose of BHV-7000 in refractory focal epilepsy.
- BHV7000-302 and the associated open-label extension study continue dosing under the updated plan.
- Biohaven paused new enrollment in its BHV-7000 program after the FDA imposed a partial clinical hold tied to a metabolite observed during rodent testing.
- More than 1,200 participants have received BHV-7000, and dosing may continue for patients already randomized.
Biohaven Ltd. (NYSE: BHVN) is pausing new enrollment in its BHV-7000 program after the FDA imposed a partial clinical hold tied to a metabolite observed during rodent testing. More than 1,200 participants have received BHV-7000 across development, and dosing can continue for patients already randomized.
BHV-7000 Enrollment Pause Leaves Lead Study on Track
The FDA’s September 4, 2026, letter applies only to new patient enrollment while additional nonclinical studies are completed. BHV7000-302 also continues dosing, but new enrollment remains paused. The associated open-label extension study continues dosing as well.
Metabolite Review and Kv7 License Shape Next Steps
The significance of the metabolite findings for humans remains uncertain, and Biohaven said the findings may be specific to rodents. The company voluntarily extended the enrollment pause plan to its global sites outside the U.S. while dosing of already randomized patients continues across the program. The license becomes effective upon closing, and both parties continue work on the required HSR submission.
FAQs
Q: Why did the FDA pause new BHV-7000 enrollment?
A: The FDA ordered a partial clinical hold after nonclinical testing identified a metabolite whose potential human risk could not yet be assessed. Additional studies are underway.
Q: Can Biohaven continue dosing in BHV-7000 trials?
A: Yes. Dosing may continue for patients already randomized across the BHV-7000 program, while new enrollment remains paused in BHV7000-302 and the associated open-label extension continues dosing.
Q: What is the status of Biohaven’s BHV-7000 data timeline?
A: BHV7000-303 is fully enrolled and randomized, and dosing continues. Across development, more than 1,200 participants have received BHV-7000, while dosing remains ongoing for already randomized patients.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.